CAR-T Immunotherapy Targeting CD19- ALL
NCT04016129
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
B-cell Leukemia
Interventions
BIOLOGICAL:
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
Sponsor
Shenzhen Geno-Immune Medical Institute